ChiCTR1900026823 版本V1.0 版本创建时间2019/10/23 20:14:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900026823 

最近更新日期:

Date of Last Refreshed on:

2019-10-23 20:11:41 

注册时间:

Date of Registration:

2019-10-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

胰肾联合移植术后糖代谢差异基因分析

Public title:

Differential gene analysis and expression of glucose metabolism after simultaneous pancreas kidney transplantation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胰肾联合移植术后糖代谢差异基因分析

Scientific title:

Differential gene analysis and expression of glucose metabolism after simultaneous pancreas kidney transplantation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘路浩 

研究负责人:

陈正 

Applicant:

Luhao Liu 

Study leader:

Zheng chen 

申请注册联系人电话:

Applicant telephone:

+86 15521117553

研究负责人电话:

Study leader's telephone:

+86 13808896300

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liuluhao2011@163.com

研究负责人电子邮件:

Study leader's E-mail:

docchenzheng@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市番禺区亚运南路63号

研究负责人通讯地址:

广州市海珠区昌岗东路250号

Applicant address:

63 Yayun Road South, Panyu District, Guangzhou, Guangdong

Study leader's address:

250 Changgang Road East, Haizhu District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州医科大学附属第二医院器官移植中心

Applicant's institution:

Organ Transplantation Center of the Second Affiliated Hospital of Guangzhou Medical University

研究负责人所在单位:

广州医科大学附属第二医院

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019-289

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

广州医科大学附属第二医院临床研究与应用伦理委员会

Name of the ethic committee:

The Second Affiliated Hospital of Guangzhou Medical University Clinical Research and Application Institutional Review Board

伦理委员会批准日期:

Date of approved by ethic committee:

2019-10-15 00:00:00

伦理委员会联系人:

陈娟

Contact Name of the ethic committee:

Juan Chen

伦理委员会联系地址:

广州市海珠区昌岗东路250号

Contact Address of the ethic committee:

250 Changgang Road East, Haizhu District, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州医科大学附属第二医院器官移植中心

Primary sponsor:

Department of Organ Transplantation, the Second Affiliated Hospital of Guangzhou Medical University

研究实施负责(组长)单位地址:

广州市番禺区亚运南路63号

Primary sponsor's address:

63 Yayun Road South, Panyu District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州医科大学附属第二医院器官移植中心

具体地址:

番禺区亚运南路63号

Institution
hospital:

Organ Transplantation Center of the Second Affiliated Hospital of Guangzhou Medical University

Address:

63 Yayun Road South, Panyu District

经费或物资来源:

自筹

Source(s) of funding:

self-financing

Target disease:

diabetic nephropathy

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

探讨胰肾联合移植术后血糖恢复的具体机制。  

Objectives of Study:

To explore the mechanism of blood glucose recovery after Simultaneous pancreas kidney transplantation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

患者确诊糖尿病肾病;无肺部感染、尿路感染;血尿CMV和BK病毒DNA均阴性,随访期间无恶性肿瘤。

Inclusion criteria

The patients were diagnosed as diabetic nephropathy, no pulmonary infection and urinary tract infection, no CMV and BK virus DNA in hematuria and no malignant tumor during follow-up.

排除标准:

基本信息不全的患者;拒绝入组的患者;血肌酐升高原因不明,二次肾移植受者;已行胰腺移植;未纠正的凝血功能障碍。

Exclusion criteria:

Patients with incomplete basic information; patients who refused to enter the group; patients with unknown cause of serum creatinine rise, secondary kidney transplantation recipients; pancreas transplantation; uncorrected coagulation dysfunction.

研究实施时间:

Study execute time:

From 2019-10-19 00:00:00 To 2020-11-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-10-19 00:00:00 To 2020-10-20 00:00:00  

干预措施:

Interventions:

组别:

接受胰肾联合移植手术的糖尿病肾病患者

样本量:

50

Group:

Diabetic nephropathy patients undergoing simultaneous pancreas kidney transplantation

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

糖尿病肾病患者

样本量:

50

Group:

Diabetic nephropathy patients

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China 

Province:

Guangdong 

City:

Guangzhou 

单位(医院):

广州医科大学附属第二医院器官移植中心 

单位级别:

三级甲等 

Institution
hospital:

Organ Transplantation Center of the Second Affiliated Hospital of Guangzhou Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

微小RNA

指标类型:

主要指标

Outcome:

miRNA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

基因

指标类型:

主要指标

Outcome:

genes

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese Clinical Trial Registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-10-23 20:11:41